Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $9.50

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received an average rating of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $9.50.

A number of research analysts have recently commented on PRQR shares. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. JMP Securities reiterated a "market outperform" rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Oppenheimer began coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an "outperform" rating and a $15.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, StockNews.com lowered shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, November 28th.

Remove Ads

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRQR. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $39,000. Woodline Partners LP bought a new position in ProQR Therapeutics in the 4th quarter valued at $9,426,000. Velan Capital Investment Management LP acquired a new position in ProQR Therapeutics in the fourth quarter worth $107,000. Squarepoint Ops LLC grew its holdings in shares of ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock worth $220,000 after purchasing an additional 11,623 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of ProQR Therapeutics by 512.8% in the fourth quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company's stock valued at $1,015,000 after buying an additional 320,614 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Trading Down 2.4 %

NASDAQ:PRQR traded down $0.04 during trading hours on Friday, hitting $1.61. 421,684 shares of the company traded hands, compared to its average volume of 551,174. ProQR Therapeutics has a twelve month low of $1.59 and a twelve month high of $4.62. The firm has a 50-day moving average of $2.14 and a 200 day moving average of $2.61. The stock has a market capitalization of $169.39 million, a price-to-earnings ratio of -5.03 and a beta of 0.24.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).